Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
40.89
+0.08 (0.20%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Travere Therapeutics stock have an average target of 40.62, with a low estimate of 25 and a high estimate of 56. The average target predicts a decrease of -0.66% from the current stock price of 40.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Travere Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 6 | 6 | 6 | 5 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $54 → $56 | Strong Buy | Maintains | $54 → $56 | +36.95% | Apr 24, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $48 → $53 | Strong Buy | Maintains | $48 → $53 | +29.62% | Apr 14, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $47 → $56 | Strong Buy | Maintains | $47 → $56 | +36.95% | Apr 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $39 → $44 | Buy | Maintains | $39 → $44 | +7.61% | Apr 14, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $49 → $54 | Strong Buy | Maintains | $49 → $54 | +32.06% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
710.38M
from 490.73M
Increased by 44.76%
Revenue Next Year
962.67M
from 710.38M
Increased by 35.51%
EPS This Year
0.17
from -0.29
EPS Next Year
1.97
from 0.17
Increased by 1,042.01%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 976.9M | 1.3B | ||||||
| Avg | 710.4M | 962.7M | ||||||
| Low | 583.1M | 715.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 99.1% | 76.7% | ||||||
| Avg | 44.8% | 35.5% | ||||||
| Low | 18.8% | 0.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.48 | 6.26 | ||||||
| Avg | 0.17 | 1.97 | ||||||
| Low | -0.64 | 0.47 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 3,530.4% | ||||||
| Avg | - | 1,042.0% | ||||||
| Low | - | 172.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.